PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference TPIP044X1/WO	FOR FURTHER ACTION	See Form PCT/IPEA/416
International application No. PCT/US05/02782	International filing date *(day/month/year)* 01 February 2005 (01.02.2005)	Priority date *(day/month/year)* 06 February 2004 (06.02.2004)

International Patent Classification (IPC) or national classification and IPC

IPC: **C07C 317/10**(2006.01);**A61K 31/165**(2006.01)
USPC: 564/162;514/618

Applicant

TRANSFORM PHARMACEUTICALS, INC CEPHALON INC.

1. This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 9 sheets, including this cover sheet.
3. This report is also accompanied by ANNEXES, comprising:
   a. ☐ *(sent to the applicant and to the International Bureau)* a total of ___ sheets, as follows:
      ☐ sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).
      ☐ sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.
   b. ☐ *(sent to the International Bureau only)* a total of (indicate type and number of electronic carrier(s)) _____ , containing a sequence listing and/or tables related thereto, in electronic form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).

4. This report contains indications relating to the following items:

☒	Box No. I	Basis of the report
☐	Box No. II	Priority
☐	Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
☐	Box No. IV	Lack of unity of invention
☒	Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
☐	Box No. VI	Certain documents cited
☐	Box No. VII	Certain defects in the international application
☒	Box No. VIII	Certain observations on the international application

Date of submission of the demand	Date of completion of this report
02 December 2005 (02.12.2005)	15 February 2006 (15.02.2006)
Name and mailing address of the IPEA/ US Mail Stop PCT, Attn: IPEA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201	Authorized officer Valerie Bell-Harrison for Thomas C. McKenzie, Ph.D. Telephone No. (571) 272-1600

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.
PCT/US05/02782

Box No. I Basis of the report

1. With regard to the language, this report is based on:
   - ☒ the international application in the language in which it was filed.
   - ☐ a translation of the international application into English, which is the language of a translation furnished for the purposes of:
     - ☐ international search (under Rules 12.3 and 23.1(b))
     - ☐ publication of the international application (under Rule 12.4(a))
     - ☐ international preliminary examination (under Rules 55.2(a) and/or 55.3(a))

2. With regard to the elements of the international application, this report is based on *(replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report)*:
   - ☒ the international application as originally filed/furnished
   - ☒ the description:
     pages 1-33 as originally filed/furnished
     pages* NONE received by this Authority on _____
     pages* NONE received by this Authority on _____
   - ☒ the claims:
     pages 34-39 as originally filed/furnished
     pages* NONE as amended (together with any statement) under Article 19
     pages* NONE received by this Authority on _____
     pages* NONE received by this Authority on _____
   - ☒ the drawings:
     pages 1/12-12/12 as originally filed/furnished
     pages* NONE received by this Authority on _____
     pages* NONE received by this Authority on _____
   - ☐ a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing.

3. ☐ The amendments have resulted in the cancellation of:
   - ☐ the description, pages _____
   - ☐ the claims, Nos. _____
   - ☐ the drawings, sheets/figs _____
   - ☐ the sequence listing (*specify*): _____
   - ☐ any table(s) related to the sequence listing (*specify*): _____

4. ☐ This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).
   - ☐ the description, pages _____
   - ☐ the claims, Nos. _____
   - ☐ the drawings, sheets/figs _____
   - ☐ the sequence listing (*specify*): _____
   - ☐ any table(s) related to the sequence listing (*specify*): _____

* *If item 4 applies, some or all of those sheets may be marked "superseded."*

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.
PCT/US05/02782

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims 1-26	YES
	Claims NONE	NO
Inventive Step (IS)	Claims 1-26	YES
	Claims NONE	NO
Industrial Applicability (IA)	Claims 1-26	YES
	Claims NONE	NO

2. Citations and Explanations (Rule 70.7)

Claims 1-26 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest the compounds, composition, or methods of these claims.

Claims 1-26 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claimed can be made or used in industry.

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY	International application No. PCT/US05/02782

Box No. VIII Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

Claims 1 and 3 are objected to, as lacking clarity under PCT Rule 66.2(a) (v) because of the claim 1 is not fully supported by the description. The description does not disclose the claimed invention in a manner sufficiently clear and complete for the claimed invention to be carried out by a person skilled in the art because: because the formation of polymorphs is completely unpredictable, Applicants lack enablement for the making of all 2:1 R:S polymorphs.

Claims 13-17 are objected to as lacking clarity under PCT Rule 66.2(a)(v) because of the claims 13-17 not fully supported by the description. The description does not disclose the claimed invention in a manner sufficiently clear and complete for the claimed invention to be carried out by a person skilled in the art because: because the formation of a specific polymorph depends upon the exact experimental conditions and solvents used to make it, Applicants lack enablement for using all solvents generally to prepare their specific four polymorphs

Claims 20-22 are objected to as lacking clarity under PCT Rule 66.2(a)(v) because of the claim 20 not fully supported by the description. The description does not disclose the claimed invention in a manner sufficiently clear and complete for the claimed invention to be carried out by a person skilled in the art because: narcolepsy treatment is the only art-recognized use of modafinil.

Claims 23-26 are objected to as lacking clarity under PCT Rule 66.2(a)(v) because of the claims 23-26 not fully supported by the description. The description does not disclose the claimed invention in a manner sufficiently clear and complete for the claimed invention to be carried out by a person skilled in the art because: crystalline solvates containing toxic solvents like chloroform, chlorobenzene, and acetic acid cannot be used clinically.

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.
PCT/US05/02782

Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

Continuation of:

P.B.5818 - Patentlaan 2
2280 HV Rijswijk (ZH)
(070) 3 40 20 40
FAX (070) 3 40 30 16

Europäisches Patentamt	European Patent Office	Office européen des brevets
Generaldirektion 1	Directorate General 1	Direction générale 1

BURGESS, Paul
Transform Pharmaceuticals, INC.
29 Hartwell Avenue
Lexington, MA 02421
ETATS-UNIS D'AMERIQUE

EPO Customer Services

Tel.: +31 (0)70 340 45 00

Date
30.06.06

Reference	Application No./Patent No.
	05712282.2 - 2103 PCT/US2005002782

Applicant/Proprietor
Transform Pharmaceuticals, Inc.

Entry into the European phase before the European Patent Office

These notes describe the procedural steps required for entry into the European phase before the European Patent Office (EPO). You are advised to read them carefully: failure to take the necessary action in time can lead to your application being deemed withdrawn.

1. The above-mentioned international patent application has been given European application No. **05712282.2**.

2. Applicants **without** a residence or their principal place of business in an EPC contracting state may themselves initiate European processing of their international applications, provided they do so before expiry of the 31st month from the priority date (see also point 6 below).

   During the European phase before the EPO as designated or elected Office, however, such applicants must be represented by a professional representative (Arts. 133(2) and 134(1), (7) EPC).

   Procedural acts performed after expiry of the 31st month by a professional representative who acted during the international phase but is not authorised to act before the EPO have no legal effect and therefore lead to loss of rights.

   Please note that a professional representative authorised to act before the EPO and who acted for the applicant during the international phase does not automatically become the representative for the European phase. Applicants are therefore strongly advised to appoint in good time any representative they wish to initiate the European phase for them; otherwise, the EPO has to send all communications direct to the applicant.

3. Applicants **with** a residence or their principal place of business in an EPC contracting state are not obliged to appoint, for the European phase before the EPO as designated or elected Office, a professional representative authorised to act before the EPO.
   However, in view of the complexity of the procedure it is recommended that they do so.

4. Applicants and professional representatives are also strongly advised to initiate the European phase using EPO Form 1200 (available free of charge from the EPO). This however is not compulsory.

5. **To enter the European phase before the EPO**, the following acts must be performed.
(N.B.: Failure validly to do so will entail loss of rights or other adverse legal consequences.)

5.1 If the EPO is acting as **designated** or **elected** Office (Arts. 22(1)(3) and 39(1) PCT respectively), applicants must, within 31 months from the date of filing or (where applicable) the earliest priority date:

a) Supply a translation of the international application into an EPO official language, if the International Bureau did not publish the application in such a language (Art. 22(1) PCT and R. 107(1)(a) EPC).
If the translation is not filed in time, the international application is deemed withdrawn before the EPO (R. 108(1) EPC).
This loss of rights is deemed not to have occurred if the translation is then filed within a two-month grace period as from notification of an EPO communication, provided a surcharge is paid at the same time (R. 108(3) EPC).

b) Pay the national basic fee (EUR 170,00) and, where a supplementary European search report has to be drawn up, the search fee (EUR 720,00 ; R. 107(1)(c) and (e) EPC).

c) If the time limit under Article 79(2) EPC expires before the 31-month time limit, pay the designation fee (EUR 80,00) for each contracting state designated (R. 107(1)(d) EPC).

d) If the time limit under Article 94(2) EPC expires before the 31-month time limit, file the written request for examination **and** pay the examination fee (EUR 1490,00 ; R. 107(1)(f) EPC).

e) Pay the third-year renewal fee (EUR 400,00) if it falls due before expiry of the 31-month time limit (R. 107(1)(g) EPC).

If the fees under (b) to (d) above are not paid in time, or the written request for examination is not filed in time, the international application is deemed withdrawn before the EPO, or the contracting-state designation(s) in question is (are) deemed withdrawn (R. 108(1) and (2) EPC). However, the fees may still be validly paid within a two-month grace period as from notification of an EPO communication, provided the necessary surcharges are paid at the same time (R. 108(3) EPC). For the renewal fee under (e) above, the grace period is **six** months from the fee's due date (Art. 86(2) EPC).

For an overview of search and examination fees, see OJ EPO 11/2005, 577 and 03/2006.

5.2 If the application documents on which the European grant procedure is to be based comprise more then ten claims, a claims fee is payable within the 31-month time limit under Rule 107(1) EPC for the eleventh and each subsequent claim (R. 110(1) EPC). The fee can however still be paid within a one-month grace period as from notification of an EPO communication pointing out the failure to pay (R. 110(2) EPC).

6. If the applicant had a representative during the application's international phase, the present notes will be sent to the representative, asking him to inform the applicant accordingly.

All subsequent communications will be sent to the applicant, or - if the EPO is informed of his appointment in time - to the applicant's European representative.

7. For more details about time limits and procedural acts before the EPO as designated and elected Office, see the EPO brochure

   How to get a European patent
   Guide for applicants - Part 2
   PCT procedure before the EPO - "Euro-PCT"

   This brochure, the list of professional representatives before the EPO, Form 1200 and details of the latest fees are now all available on the Internet under

   http://www.european-patent-office.org

Receiving section